Posted by Michael Wonder on 10 Feb 2021
FDA authorises monoclonal antibodies for treatment of COVID-19
9 February 2021 - Today, the U.S. FDA issued an emergency use authorisation for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age or older weighing at least 40 kilograms) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.
The authorised use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions.
